Loading stock data…
$15.37-0.34 (-2.16%)
Latigo Biotherapeutics, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$25.81M↓ | -$23.44M↑ | -$25.75M↓ | -$21.51M |
| Net Income | -$25.80M↓ | -$22.96M↑ | -$25.84M↓ | -$20.95M |
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing...